Press Releases

Emplicure's patch technology receives US patent approval

The United States Patent and Trademark Office granted a patent to Emplicure on 9th April 2019 for its patch technology. This patent provides protection for Emplicure's transdermal patch with abuse deterrent properties for the treatment of chronic pain until September 2031.

"Both USA and Europe are important markets for Emplicure and to get approvals of patent applications in these territories are important steps in the product and business development", says Susanne Bredenberg, CEO at Emplicure.

The protection provided by this patent should extend to future, related products that are in development based on this technology. A patent for this technology was also granted by the European Patent Office in 2017.

For more information, please contact:

Susanne Bredenberg, CEO Emplicure

Phone: + 46 (0)70 859 77 99


About Emplicure

Emplicure is a research and development focused pharmaceutical company based in Uppsala, Sweden. The company develops new patentable pharmaceutical products based on drug delivery platform technologies originating from the interface between the materials and pharmaceutical sciences. Emplicure currently has several products in the pipeline in formulation or preclinical development phase. The first product to enter the clinical phase is a transdermal patch with abuse deterrent properties for the treatment of chronic pain. The products will be sold or out licensed at different development stages to larger pharmaceutical companies.


Emplicure AB has developed the formulation of Empli03 to be used for GMP manufacturing for the first clinical study. Agreement has been signed with Quotient Sciences, UK, who will be responsible for the manufacturing and will also perform the first pharmacokinetic study.


Emplicure AB announces today that the Nomination Committee for the annual general shareholders meeting (AGM) in April 2022 is formed. The Nomination Committee consists of representatives nominated by the three largest shareholders per the last bank-day in the third quarter, as well as the Chairman of the Board. Emplicure's three largest shareholders, also the founders, have agreed to vote as one, in order to to give preference for more shareholders.


Emplicure AB has received issue notification from the US Patent and Trademark Office that a formal approval of the inhalation platform of pharmaceuticals will be issued on December 21, 2021.


Erik Magnusson appointed new Chief Financial Officer (CFO) in Emplicure AB.


Following this summer's new share issue and subsequent IPO, we are well equipped. The focus of the third quarter has been on shifting up, and driving the development of the company's two main projects; Empli03, our drug candidate for chronic pain, and Amp01, our oral tobacco-free nicotine product in the form of dry, white pouches as a consumer product. Both projects are developed on our own bioceramic and patented technologies and platforms.


Anna-Lena Nicolson, CFO och medlem i ledningsgruppen i Emplicure AB (publ), har idag beslutat att lämna sitt uppdrag. Anna-Lena kommer att kvarstå som CFO till och med den 31 december 2021. Processen med att rekrytera hennes ersättare har inletts.


Emplicure AB (publ) har anställt Anna Franzén som Sr. Manager Clinical Projects för att driva och utveckla bolagets kliniska projekt.



Do you want to know more?

Contact us today.